SCHEMBL30962941

SCHEMBL30962941

COc1nc(Nc2ccc(C3CCN(C)CC3)c(C)c2)ncc1C(=O)Nc1cc(O[Si](C)(C)C(C)(C)C)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 3/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ KDR P35968 1/20 0.44
▸ TEK Q02763 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ WEE1 P30291 2/20 0.44
▸ BRD4 O60885 9/20 0.42
▸ JAK2 O60674 2/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ BRDT Q58F21 1/20 0.41
▸ EGFR P00533 2/20 0.39
▸ SRC P12931 1/20 0.38
▸ PTK2 Q05397 1/20 0.38
▸ SIK1 P57059 1/20 0.38
▸ SIK2 Q9H0K1 1/20 0.38
▸ SIK3 Q9Y2K2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30962922 0.88 WEE1 (0.44) LCKJAK3KDRTEKMAPK14
SCHEMBL30962737 0.87 WEE1 (0.48) LCKJAK3KDRTEKMAPK14
SCHEMBL30962908 0.87 WEE1 (0.43) LCKJAK3KDRTEKMAPK14
SCHEMBL27313552 0.86 WEE1 (0.52) LCKJAK3KDRTEKMAPK14
SCHEMBL30962624 0.86 WEE1 (0.52) LCKJAK3KDRTEKMAPK14
SCHEMBL30962687 0.85 WEE1 (0.48) LCKJAK3KDRTEKMAPK14
SCHEMBL30962834 0.85 WEE1 (0.46) LCKJAK3KDRTEKMAPK14
SCHEMBL30962817 0.84 LCK (0.43) LCKJAK3KDRTEKMAPK14
SCHEMBL27313416 0.83 WEE1 (0.54) LCKJAK3KDRTEKMAPK14
SCHEMBL30962770 0.82 LCK (0.51) LCKJAK3KDRTEKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 — — WO disclosed
Send feedback